ISO 18562-2:2024
Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 2: Tests for emissions of particulate matter
Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 2: Tests for emissions of particulate matter
- Статус документа:
- Действующий
- Формат:
- Электронный (PDF)
- Количество страниц:
- 16
- Дата публикации:
- 8 марта 2024 г.
- Издание:
- ISO IS 18562 edition 2 version 1
- ICS:
- 11.040.10
This document specifies tests for the emissions of particulate matter from the gas pathways of a medical device, its parts or accessories, which are intended to provide respiratory care or supply substances via the respiratory tract to a patient in all environments. The tests of this document are intended to quantify particles from 0,25 µm diameter to 10 µm diameter that are emitted by the medical device, its parts or accessories into the respirable gas stream. This document establishes acceptance criteria for these tests. This document does not address nanoparticles. Insufficient data exist to establish exposure limits for particles less than 0,25 µm diameter. This document does not address particles larger than 10 µm diameter. These particles are deposited in the nasal cavity. Additional information can be needed for medical devices or accessories that bypass the nose. This is outside the scope of this document but can be required by some authorities having jurisdiction. This document therefore adopts the same approach as the US Environmental Protection Agency (EPA) in setting limits based solely on particle size and not their chemistry. This document addresses potential contamination of the gas stream arising from the gas pathways, which is then conducted to the patient. This document applies over the expected lifetime of the medical device in normal use and takes into account the effects of any intended processing. This document does not address biological evaluation of the particles that are deliberately released by a nebulizer (i.e. the therapeutic agent). This document does not address biological evaluation of the surfaces of gas pathways that have direct contact with the patient. The requirements for direct contact surfaces are found in the ISO 10993 series. Medical devices, parts or accessories, containing gas pathways that are addressed by this document, include, but are not limited to, ventilators, anaesthesia workstations (including gas mixers), breathing systems, oxygen conserving devices, oxygen concentrators, nebulizers, low-pressure hose assemblies, humidifiers, heat and moisture exchangers, respiratory gas monitors, respiration monitors, masks, medical respiratory personal protective equipment, mouth pieces, resuscitators, breathing tubes, breathing systems filters, Y-pieces, and any breathing accessories intended to be used with such devices. The enclosed chamber of an incubator, including the mattress, and the inner surface of an oxygen hood are considered to be gas pathways and are also addressed by this document. This document does not address contamination already present in the gas supplied from the gas sources while medical devices are in normal use. EXAMPLE Contamination arriving at the medical device from gas sources such as medical gas pipeline systems (including the non-return valves in the pipeline outlets), outlets of pressure regulators connected or integral to a medical gas cylinder or room air taken into the medical device is not addressed by ISO 18562 (all parts).
Abstract
Overview
ISO 18562-2:2024 specifies how to evaluate particulate matter emissions from breathing gas pathways in healthcare applications. It is part of the ISO 18562 series on biocompatibility evaluation of breathing gas pathways and focuses on quantifying respirable particles from 0.25 µm to 10 µm emitted by medical devices, parts or accessories that deliver gases or substances via the respiratory tract. The standard establishes acceptance criteria (based on particle size, not chemistry) and test methods to assess contamination generated within device gas pathways over the expected device lifetime and after intended processing.
Key technical topics and requirements
- Scope: Applies to gas pathways of ventilators, anaesthesia workstations, breathing systems, oxygen concentrators, nebulizers, humidifiers, masks, incubator chambers/hoods and similar devices. It does not address:
- nanoparticles (< 0.25 µm) or particles > 10 µm,
- contamination already present in the incoming gas supply,
- biological evaluation of deliberate therapeutic aerosols or surfaces in direct patient contact (ISO 10993 covers surfaces).
- Particle size range: Test methods quantify particles between 0.25 µm and 10 µm.
- Acceptance criteria: Adopts EPA-based mass concentration limits for continuous exposure:
- PM2.5 (≤ 2.5 µm): 12 µg/m3
- PM10 (≤ 10 µm): 150 µg/m3
- Testing approaches: Multiple methods to suit diverse devices, including:
- Single filter test setup (captures particles ≥ 0.25 µm),
- Double filter test setup,
- Measurement by particle counters and size-specific analysis.
- Risk-based application: Testing is applied following the risk-management strategy in ISO 18562-1, taking into account device lifetime, manufacturing/processing, transport/storage and worst-case patient exposure.
- Reporting: Test selection, sample preparation, duration and results must be documented and linked to the device risk file.
Practical applications - who uses this standard
- Medical device manufacturers (design, R&D, quality assurance) use ISO 18562-2:2024 to demonstrate that internal gas pathways do not introduce harmful particulate levels.
- Regulatory and compliance teams for premarket submissions and conformity assessments.
- Independent test laboratories and biomedical test engineers conducting particulate emissions testing.
- Clinical engineers and hospital procurement teams evaluating device safety for respiratory care environments.
- Notified bodies and auditors assessing device biocompatibility and safety documentation.
Related standards and guidance
- ISO 18562-1:2024 - Evaluation and testing within a risk management process (companion document defining strategy).
- ISO 10993 series - Biological evaluation of medical device materials (for direct-contact surfaces).
- References to IMDRF and EU MDR essential principles are included in ISO 18562-2 for regulatory alignment.
Keywords: ISO 18562-2:2024, biocompatibility, breathing gas pathways, particulate matter emissions testing, particle size 0.25 µm–10 µm, PM2.5, PM10, medical device testing, particle counter, single filter test.
Технические детали
- Технический комитет
- ISO/TC 121/SC 3 - Respiratory devices and related equipment used for patient care
- SKU
- ISO 18562-2:2024
Похожие стандарты
Стандарты, упомянутые в описании
ISO 18562-1:2024
ДействующийBiocompatibility evaluation of breathing gas pathways in healthcare applications — Part 1: Evaluation and tes…
Overview ISO 18562-1:2024 provides a comprehensive framework for the biocompatibility evaluation of breathing gas pathways in medical devices used in healthcare settings. This standard is fundamental…
ISO 18562-3:2024
ДействующийBiocompatibility evaluation of breathing gas pathways in healthcare applications — Part 3: Tests for emission…
Overview ISO 18562-3:2024 - "Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 3: Tests for emissions of volatile organic substances" specifies laboratory tests…